The British Society of Echocardiography (BSE)’s Research and Audit Committee has partnered with a research team from University College London Hospitals NHS Foundation Trust to provide a new survey auditing the impact of the 2021 cardio-oncology guideline.
The subspecialty of cardio-oncology aims to reduce cardiovascular morbidity and mortality in patients with cancer or following cancer treatment. Cancer therapy can lead to a variety of cardiovascular complications, including left ventricular systolic dysfunction, pericardial disease, and valvular heart disease. Echocardiography is a key diagnostic imaging tool in the diagnosis and surveillance for many of these complications. The baseline assessment and subsequent surveillance of patients undergoing treatment with anthracyclines and/or human epidermal growth factor (EGF) receptor (HER) 2-positive targeted treatment (e.g. trastuzumab and pertuzumab) form a significant proportion of cardio-oncology patients undergoing echocardiography.
The 2021 guideline, British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab, outlined a protocol for a protocol for baseline and surveillance echocardiography of patients undergoing treatment with anthracyclines and/or trastuzumab, including the methodology for acquisition of images and echocardiographic definitions for considering cancer therapeutics-related cardiac dysfunction.
This short survey will be used to assess how these guidelines have been implemented across the UK, and how this could be optimised in the future. Data provided will be anonymised so individual responses will not be identifiable to a particular institution. The survey should be completed by echo leads and will take approximately five minutes to complete. If you have any questions please contact Dr Arjun Ghosh.
Complete the survey